CAPR · Capricor Therapeutics, Inc.
$8.37
+0.84% last session
End-of-day data · close of 2026-09-11
Market cap
$0B
Enterprise value
$0B
Trailing P/E
—
Forward P/E
-5.6
Dividend yield
—
Beta
0.72
Avg volume
6M
Employees
0K
Daily Change %
0.84%
5 Days Change
-8.09%
10 Days Change
-12.82%
30 Days Change
119.85%
60 Days Change
-59.83%
Month to Day Change
-13.69%
Year to Day Change
-70.06%
Analyst Outlook
Analyst estimates change daily — follow the shifts on the Estimate Trends page.
Technical Analysis
Analyst sentiment over time — CAPR
Rec Mean (blue, left — higher = more bullish) vs. price targets (right).
Investment Bank Ratings as of 2026-09-01
Latest call per bank · past 12 months
Recent rating actions
| Date | Firm | Action | Rating | Price target |
|---|---|---|---|---|
| 2026-09-01 | Piper Sandler | Upgrade | Neutral → Overweight | $2.00 → $25.00 |
| 2026-08-14 | Cantor Fitzgerald | Upgrade | Neutral → Overweight | $3.50 → $28.00 |
| 2026-07-31 | Jones Trading | Downgrade | Buy → Hold | $0.00 |
| 2026-07-30 | Piper Sandler | Downgrade | Overweight → Neutral | $58.00 → $2.00 |
| 2026-07-30 | Cantor Fitzgerald | Downgrade | Overweight → Neutral | $62.00 → $3.50 |
| 2026-07-30 | HC Wainwright & Co. | Downgrade | Buy → Neutral | $0.00 |
| 2026-05-13 | HC Wainwright & Co. | Reiterates | Buy | $60.00 |
| 2026-03-13 | B. Riley Securities | Maintains | Buy | $50.00 → $63.00 |
Ratings and price targets are the published opinions of the issuing banks, compiled from Yahoo Finance rating actions — not investment advice.
Signal Summary as of 2026-09-11
- RSI (14): RSI is 44 — neutral momentum, neither overbought nor oversold.
- Price vs 50-day MA: Trading 26.1% below the 50-day MA ($11.32).
- Price vs 200-day MA: Trading 64.3% below the 200-day MA ($23.43).
- MA cross: The 50-day MA sits below the 200-day MA (death-cross regime) — the longer-term trend points down.
- MACD (12,26,9): MACD histogram is positive (+0.30) — short-term momentum is improving.
- 52-week range: Price sits between the 52-week low ($3.85) and high ($35.34).
CAPR Price Chart
Loading chart for CAPR…
Fundamentals
About Capricor Therapeutics, Inc.
Capricor Therapeutics, Inc., a clinical-stage biotechnology company, engages in the development of transformative cell and exosome-based therapeutics for treating duchenne muscular dystrophy (DMD) and other diseases with unmet medical needs in the United States. Its lead product candidate is the Deramiocel, an allogeneic cardiosphere-derived cells, which is in phase 3 clinical trial for the treatment of DMD. The company also develops Exosome protein-based vaccine, which is in preclinical trial to treat SARS-CoV-2; StealthX Exosome Platform, and exosome platform program consists of engineered exosomes for vaccine and therapeutic development and is in preclinical trial. In addition, it engages in developing StealthX, an engineered exosome-based vaccine candidate, under phase 1 clinical study for a range of therapeutic applications, including targeted RNA, protein, and small molecule therapeutics to treat or prevent a variety of diseases; It has license agreement with Johns Hopkins University, University of Rome License, and Cedars-Sinai Medical Center to develop and commercialize licensed products and licensed services under the licensed patent rights in all fields and a nonexclusive right to the know-how; Cell Line License Agreement with Life Technologies for the development of exosomes platform. The company was founded in 2005 and is headquartered in San Diego, California.
More in Biotechnology
VRTX
Vertex Pharmaceuticals Incorpor
$130B 14.9% YTD
REGN
Regeneron Pharmaceuticals, Inc.
$82B 5.0% YTD
ARGX
argenx SE
$62B 19.2% YTD
MRNA
Moderna, Inc.
$55B 359.9% YTD
RVMD
Revolution Medicines, Inc.
$44B 160.7% YTD
ONC
BeOne Medicines Ltd.
$39B 15.5% YTD
RPRX
Royalty Pharma plc
$34B 59.0% YTD
ALNY
Alnylam Pharmaceuticals, Inc.
$33B -35.1% YTD
Data is sourced from end-of-day snapshots and refreshed daily before the US market open — nothing on this page is real-time. Figures can contain vendor errors. This page is for information only and is not investment advice.